Infusion of plasma-derived mannan-binding lectin (MBL) into MBL-deficient humans.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationBiochem Soc Trans. 2003, 31(Pt 4):768-9
AbstractOur first experience of mannan-binding lectin (MBL)-replacement therapy was with a patient experiencing recurrent erythema multiforme associated with reactivation of herpes simplex virus; his erythematous eruptions could be controlled with infusions of fresh frozen plasma containing MBL, but not with plasma lacking MBL. Some years later, we treated a young girl with recurrent, debilitating infections with purified MBL; this was also followed by a dramatic clinical improvement. We have now carried out a phase I clinical trial on 20 MBL-deficient, but healthy, adult volunteers. The MBL was prepared by the State Serum Institute in Copenhagen, Denmark, from blood donor plasma. Each volunteer received a total of 18 mg of MBL in three 6-mg doses given intravenously once a week over 3 weeks. The volunteers were monitored closely after each infusion and no adverse clinical or laboratory effects were observed. Laboratory parameters included C-reactive protein, various complement components, and antibodies to MBL, HIV and hepatitis viruses. C3a (the anaphylotoxin derived from complement component C3) was monitored for signs of complement activation, but no significant infusion-associated fluctuations were observed. Serum levels of MBL after each 6-mg infusion ranged between 1200 and 2500 ng/ml. The half-life of the infused MBL was about 70 h, or 3 days. It was concluded that infusion of purified MBL manufactured by the Danish State Serum Institute is a safe procedure. However, adults may have to be given 6 mg or more at least twice weekly to maintain protective plasma MBL levels in MBL-deficient individuals.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Human plasma-derived mannose-binding lectin: a phase I safety and pharmacokinetic study.
- Authors: Valdimarsson H, Vikingsdottir T, Bang P, Saevarsdottir S, Gudjonsson JE, Oskarsson O, Christiansen M, Blou L, Laursen I, Koch C
- Issue date: 2004 Jan
- Mannan-binding lectin (MBL) production from human plasma.
- Authors: Laursen I
- Issue date: 2003 Aug
- Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaenia.
- Authors: Frakking FN, Brouwer N, van de Wetering MD, Budde IK, Strengers PF, Huitema AD, Laursen I, Houen G, Caron HN, Dolman KM, Kuijpers TW
- Issue date: 2009 Mar
- Mannose-binding lectin (MBL) substitution: recovery of opsonic function in vivo lags behind MBL serum levels.
- Authors: Brouwer N, Frakking FN, van de Wetering MD, van Houdt M, Hart M, Budde IK, Strengers PF, Laursen I, Houen G, Roos D, Jensenius JC, Caron HN, Dolman KM, Kuijpers TW
- Issue date: 2009 Sep 1
- Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans.
- Authors: Valdimarsson H, Stefansson M, Vikingsdottir T, Arason GJ, Koch C, Thiel S, Jensenius JC
- Issue date: 1998 Aug